CalciMedica, Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica, Inc. (NASDAQ:CALC) was the recipient of a significant decline in short interest in December. As of December 31st, there was short interest totalling 61,300 shares, a decline of 6.6% from the December 15th total of 65,600 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 59,400 shares, the days-to-cover ratio is presently 1.0 days.

CalciMedica Stock Down 2.5 %

Shares of CalciMedica stock traded down $0.08 during trading on Friday, hitting $3.09. 21,907 shares of the company were exchanged, compared to its average volume of 25,828. CalciMedica has a fifty-two week low of $2.05 and a fifty-two week high of $8.38. The firm has a 50 day moving average price of $3.13 and a 200 day moving average price of $3.86. The stock has a market capitalization of $41.65 million, a price-to-earnings ratio of -2.86 and a beta of 1.22.

Insider Activity at CalciMedica

In related news, major shareholder Sanderling Venture Partners Vi acquired 86,867 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were purchased at an average price of $3.75 per share, with a total value of $325,751.25. Following the completion of the acquisition, the insider now owns 814,300 shares in the company, valued at approximately $3,053,625. This represents a 11.94 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Fred A. Middleton bought 87,744 shares of the company’s stock in a transaction on Friday, November 1st. The stock was bought at an average cost of $3.75 per share, with a total value of $329,040.00. Following the completion of the acquisition, the director now owns 814,300 shares of the company’s stock, valued at $3,053,625. This represents a 12.08 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 252,744 shares of company stock worth $942,510 over the last three months. 41.55% of the stock is currently owned by corporate insiders.

Institutional Trading of CalciMedica

A number of large investors have recently made changes to their positions in CALC. PVG Asset Management Corp purchased a new position in CalciMedica in the 3rd quarter valued at about $67,000. Atria Investments Inc raised its position in shares of CalciMedica by 136.5% in the third quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock valued at $117,000 after buying an additional 15,296 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of CalciMedica by 51.2% during the third quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock valued at $295,000 after buying an additional 22,525 shares during the period.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of CalciMedica in a report on Thursday, November 14th.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.